Related Experiment Video

Updated: Oct 22, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer

Daniel A Vallera1,2, Felix Oh1,2, Behiye Kodal1,3

  • 1Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.

Cancers
|August 27, 2021
PubMed

Insights

A novel tri-specific killer engager (TriKE) shows promise for ovarian cancer immunotherapy by combining HER2 targeting with enhanced natural killer (NK) cell function.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • Antibodies targeting HER2, like trastuzumab and pertuzumab, are effective in breast cancer but show limited success in ovarian cancer.
  • Current immunotherapy strategies often focus on stimulating the innate immune system, with natural killer (NK) cell enhancement being a promising but not yet mainstream approach.

Purpose of the Study:

  • To develop and evaluate a novel bioengineered molecule, CAM1615HER2, for ovarian cancer treatment.
  • To assess the efficacy of this molecule in enhancing natural killer (NK) cell-mediated cancer cell killing.

Main Methods:

  • Development of a tri-specific killer engager (TriKE) platform incorporating a camelid VHH antibody fragment recognizing CD16, a single chain variable fragment (scFv) recognizing HER2, and the interleukin-15 (IL-15) cytokine.
  • In vitro testing against human ovarian cancer cell lines.
  • In vivo evaluation using a human ovarian cancer xenograft model with engrafted cancer and NK cells.

Main Results:

  • The TriKE molecule demonstrated in vitro effectiveness in killing ovarian cancer cell lines.
  • Significant anti-cancer effects were observed in vivo, showing potent therapeutic potential.
  • The engineered molecule successfully combined tumor targeting with immune cell activation.

Conclusions:

  • The novel TriKE platform, CAM1615HER2, represents a promising advancement in ovarian cancer immunotherapy.
  • Integrating tumor-specific targeting with cytokine-mediated immune cell enhancement within a single molecule may overcome limitations of previous HER2-targeted therapies.
  • This approach warrants further investigation for its potential to improve outcomes in ovarian cancer patients.
Keywords:
ADCCHER2IL-15NK cellsTriKEsbispecific antibodiescarcinomainnate immunotherapyovarian cancer

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.7K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
771
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K